OUD

BioCorRx Reports Business Update for 2023

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Substance abuse, Bupropion, CFO, Risk, Public, OUD, Research, Security (finance), Opioid use disorder, NIH, Naltrexone, Bangladesh Technical Education Board, MUD, OTCQB, Pharmaceutical industry

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD).
  • We successfully decreased our total operating expenses by over $1.0 million for the year ending December 31, 2023, compared to the previous year.
  • Overall, we are optimistic about the business outlook and look forward to continuing to develop medicines.

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 2, 2024
Research, Frost, Patent, Partnership, Patient, OUD, G&A, Opioid use disorder, Addiction, GLEN, Consultant, Pharmaceutical industry

GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.

Key Points: 
  • GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
  • Specifically, we conducted meetings and received favorable feedback from both US and European regulators, allowing us to refine our clinical development plan.
  • Cash and cash equivalents were $2.8 million as of December 31, 2023, compared to $4.0 million as of December 31, 2022.
  • Net Loss was $5.1 million for the year ended December 31, 2023, compared to a net loss of $12.7 million for the year ended December 31, 2022.

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, Depression, Congress, PD, Patient, OUD, CIAS, Sale, G&A, DMT, Șaeș, Pivotal, Psilocybin, Atai, TRD, Investment, Ibogaine, Pharmacokinetics, Safety, PTSD, OTF, Pharmaceutical industry

“In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.

Key Points: 
  • “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc., streamlining clinical, general and administrative operations.
  • atai realized operational efficiencies by simplifying and optimizing its organizational structure in line with its revised business and pipeline priorities.
  • In August 2023, the Phase 1 study results demonstrated that 9 mg/kg of oral ibogaine leads to robust psychedelic experiences.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder

Retrieved on: 
Thursday, March 14, 2024
Patient, Public, OUD, Research, Columbia University, Opioid use disorder, IND, GMP, Report, Ibogaine, Toxicology, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders. As summarized in a recent New York Times article (Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction), ibogaine, a plant-derived psychoactive compound, has accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.

Key Points: 
  • However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity.
  • This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials in healthy volunteers and opioid use disorder (OUD) patients for GM-3009.
  • The planned clinical work will seek to confirm that GM-3009 eliminates the cardiovascular risks associated with ibogaine and demonstrate proof-of-concept efficacy in attenuating symptoms associated with OUD.
  • As Gilgamesh moves forward with its clinical trials, the company is poised to lead a new era in addiction treatment, marked by safer, more effective, and scientifically validated therapies.

Telehealth addiction treatment offers exceptional outcomes for pregnant people with opioid use disorder

Retrieved on: 
Thursday, March 14, 2024
ANN, Health, Patient, OUD, Research, Buprenorphine, Mortality, Opioid use disorder, Pregnancy, Small business, American College, Drug, MPH, Privacy, Mortal Kombat, Dietary supplement

ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Workit Labs, the research and development arm of Workit Health, today published a promising analysis of patients who were pregnant and received telehealth treatment for opioid use disorder. As opioid use disorder (OUD) is a growing risk factor for perinatal death, research in this field is increasingly vital.

Key Points: 
  • ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Workit Labs, the research and development arm of Workit Health, today published a promising analysis of patients who were pregnant and received telehealth treatment for opioid use disorder.
  • As opioid use disorder (OUD) is a growing risk factor for perinatal death, research in this field is increasingly vital.
  • It can be challenging for people who are pregnant and living with opioid use disorder to find addiction treatment.
  • "It can be extremely challenging for people who are pregnant and living with opioid use disorder to find addiction treatment," said Lira.

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Retrieved on: 
Wednesday, February 28, 2024
OUD, Opioid use disorder, Intellectual property, Patent, Pharmaceutical industry

CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.

Key Points: 
  • CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office.
  • The patent covers the Company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder (OUD).
  • “We are proud to be awarded another important patent that broadens our Intellectual Property portfolio and covers meaningful aspects of our lead asset, AD04, including its unique ability to target the serotonin transporter gene,” commented Cary Claiborne, CEO of Adial Pharmaceuticals.
  • “We believe AD04 has significant potential to treat OUD and other drug dependencies in addition to our initial indication of alcohol use disorder.

Groups Recover Together’s First Annual Outcomes Report Demonstrates Industry-Leading Results and Calls for Transparency in Data

Retrieved on: 
Thursday, February 22, 2024
Mental Health, Health, Other Health, Managed Care, General Health, Pharmaceutical, Social support, OUD, Opioid use disorder, Mortality, Housing, Education, Annual report, Employment, Pharmaceutical industry

The annual report demonstrates the organization’s success in working toward its mission: saving lives by increasing access to communities of recovery in the places where they’re needed most.

Key Points: 
  • The annual report demonstrates the organization’s success in working toward its mission: saving lives by increasing access to communities of recovery in the places where they’re needed most.
  • The report also invites providers to commit to increasing their own transparency and quality of services.
  • We hope our transparency inspires industry leaders to join us in sharing outcomes,” said Dr. Jacob “Gus” Crothers, the Chief Medical and Outcomes Officer at Groups Recover Together.
  • Read and download Groups Recover Together’s 2023 annual report.

Study Shows In-Network Insurance Coverage Significantly Improves Opioid Use Disorder Treatment Retention

Retrieved on: 
Tuesday, March 5, 2024
Patient, OUD, Health, Insurance, Opioid use disorder, Medicaid, Opioid, CMS, Policy, Health insurance

Published in Health Affairs , the peer-reviewed study found that patients receiving opioid treatment via in-network insurance overwhelmingly (72.3%) stayed in treatment for at least 180 days in comparison to those who were either out-of-network or uninsured and paying for treatment with cash.

Key Points: 
  • Published in Health Affairs , the peer-reviewed study found that patients receiving opioid treatment via in-network insurance overwhelmingly (72.3%) stayed in treatment for at least 180 days in comparison to those who were either out-of-network or uninsured and paying for treatment with cash.
  • Results highlight how insurance status impacts treatment retention rates and that not having in-network benefits can create a significant financial hurdle to receiving quality, life-saving care.
  • Conducted from January to September 2022, the study analyzed 3,842 patients – 1,613 in-network patients and 2,229 cash-pay patients – with opioid use disorder (OUD) receiving evidence-based medications for OUD treatment via telehealth from Ophelia.
  • The study results highlighted a disparity in treatment retention rates that was simply not a difference between insured and uninsured patients.